Carboplatin Research

Despite having been used widely for over 15 years, carboplatin and similar drugs continue to inspire quite a bit of scientific research.

Report on four-drug combination therapy success.

A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance.

Report spells out ototoxic risks of platinum-based chemotherapy and radiotherapy

Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells.

Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma.

Does weight matter in determining dosage?

DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells

Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Does a nanomolecule of Carboplatin injected periocularly help in attaining higher intravitreal concentrations?

Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.

Single-dose carboplatin as effective as radiation for early testicular cancer

Advanced Cervical Cancer Can Be Successfully Downstaged With Pre-Surgery Carboplatin And Docetaxel

Advances in platinum chemotherapy from RSC

Pharmacologic Study of Infusional Topotecan and Carboplatin in Relapsed and Refractory Acute Leukemia

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.

A phase II trial of carboplatin for intraocular retinoblastoma.

Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors.

Carboplatin May Be Less Toxic Than Radiation for Seminoma - One shot of carboplatin appeared to be as effective as radiation therapy in treating early seminoma, a kind of testicular cancer, and also appeared safer, reducing the risk of second cancers.

Clinical trials involving carboplatin - from the NIH

Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.

Phase II study of carboplatin combined with weekly docetaxel in patients with advanced non-small cell lung cancer.

Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report.